The overexpression of C-erb B-2 oncogene in breast cancer was examined in 245 cases with immunohistochemical techniques.The results showed that:①Significant associations of C-erb B-2 overexpression with high histological grade (Ｐ＜0.05), positive axillary node status (Ｐ＜0.05)， advanced clinical stage (Ｐ＜0.05) and the absence of hormone receptor(Ｐ＜0.05) were identified in breast cancer.②Overexpression of C-erb B-2 oncogene was related with 5-year and 10-year survival rate, and considered as a prognostic factor for breast cancer independent of axillary node status. Detection of C-erb B-2 oncogene overexpression could be arranged as a regular pathological examination in breast cancer.Combined with axillary node and estrogen receptor, progestin receptor status, the results can be used in determining the prognosis and planing the treatment programme in breast cancer.
Citation：
Xing Tianyong,Yang Jingqiao,Zhou Leilei.. RELATIONSHIP BETWEEN C-erb B-2 ONCOGENE OVEREXPRESSION AND ESTROGEN RECEPTOR, PROGESTIN RECEPTOR IN BREAST CANCER AND ITS PROGNOSTIC SIGNIFICATION. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 1999, 6(1): 21-23. doi:
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
姚先莹. 乳腺疾病激素受体的研究小结. 四川医学， 1981； 2(1)∶69.
|
| 2. |
Porter PL, Garcia R, Moe R, et al. Cerb B2 oncogene protein in situ and invasive lobular breast neoplasia. Cancer, 1991; 68(2)∶331.
|
| 3. |
Allred DC, Clark GM, Molina R, et al. Overexpression of Her2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology, 1992; 23(9)∶947.
|
| 4. |
Zhou D, Dattifora H, Yokota J, et al. Association of multiple copies of the Cerb B2 oncogene with spread of breast cancer. Cancer Res, 1987; 47(22)∶6123.
|
| 5. |
May E, Mouriesse H, MayLevin F, et al. Human breast cancer: identification of populations with a high risk of early relapse in relation to both estrogen receptor status and Cerb B2 overexpression. Br J Cancer, 1990; 62(3)∶430.
|
| 6. |
Richard M, Elledge MD, Daniel R, et al. Estrogen receptor, progesteroner receptor and HER 2/neu protein in breast cancers from pregnancy patients. Cancer, 1993; 71(8)∶2499.
|
| 7. |
Wright C, Niebolson S, Angus B, et al. Relationship between Cerb B2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer, 1992; 65(1)∶118.
|
| 8. |
Borg A, Tandon AK, Sigurdsson H, et al. Her2/neu amplification predicts poor survival in nodepositive breast cancer.Cancer Res, 1990; 50(14)∶4332.
|
- 1. 姚先莹. 乳腺疾病激素受体的研究小结. 四川医学， 1981； 2(1)∶69.
- 2. Porter PL, Garcia R, Moe R, et al. Cerb B2 oncogene protein in situ and invasive lobular breast neoplasia. Cancer, 1991; 68(2)∶331.
- 3. Allred DC, Clark GM, Molina R, et al. Overexpression of Her2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology, 1992; 23(9)∶947.
- 4. Zhou D, Dattifora H, Yokota J, et al. Association of multiple copies of the Cerb B2 oncogene with spread of breast cancer. Cancer Res, 1987; 47(22)∶6123.
- 5. May E, Mouriesse H, MayLevin F, et al. Human breast cancer: identification of populations with a high risk of early relapse in relation to both estrogen receptor status and Cerb B2 overexpression. Br J Cancer, 1990; 62(3)∶430.
- 6. Richard M, Elledge MD, Daniel R, et al. Estrogen receptor, progesteroner receptor and HER 2/neu protein in breast cancers from pregnancy patients. Cancer, 1993; 71(8)∶2499.
- 7. Wright C, Niebolson S, Angus B, et al. Relationship between Cerb B2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer, 1992; 65(1)∶118.
- 8. Borg A, Tandon AK, Sigurdsson H, et al. Her2/neu amplification predicts poor survival in nodepositive breast cancer.Cancer Res, 1990; 50(14)∶4332.
